- Home
- REVB vs CNEY Comparison
REVB vs CNEY Comparison
Compare REVB & CNEY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- CNEY
- Stock Information
- Founded
- REVB 2020
- CNEY 2018
- Country
- REVB United States
- CNEY China
- Employees
- REVB N/A
- CNEY N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- CNEY Major Chemicals
- Sector
- REVB Health Care
- CNEY Industrials
- Exchange
- REVB Nasdaq
- CNEY Nasdaq
- Market Cap
- REVB 2.3M
- CNEY 2.1M
- IPO Year
- REVB N/A
- CNEY 2021
- Fundamental
- Price
- REVB $2.67
- CNEY $0.14
- Analyst Decision
- REVB
- CNEY
- Analyst Count
- REVB 0
- CNEY 0
- Target Price
- REVB N/A
- CNEY N/A
- AVG Volume (30 Days)
- REVB 141.4K
- CNEY 504.6K
- Earning Date
- REVB 03-06-2025
- CNEY 01-01-0001
- Dividend Yield
- REVB N/A
- CNEY N/A
- EPS Growth
- REVB N/A
- CNEY N/A
- EPS
- REVB N/A
- CNEY N/A
- Revenue
- REVB N/A
- CNEY $50,957,974.00
- Revenue This Year
- REVB N/A
- CNEY N/A
- Revenue Next Year
- REVB N/A
- CNEY N/A
- P/E Ratio
- REVB N/A
- CNEY N/A
- Revenue Growth
- REVB N/A
- CNEY N/A
- 52 Week Low
- REVB $2.36
- CNEY $0.12
- 52 Week High
- REVB $60.80
- CNEY $1.60
- Technical
- Relative Strength Index (RSI)
- REVB 32.04
- CNEY 31.01
- Support Level
- REVB $2.51
- CNEY $0.12
- Resistance Level
- REVB $2.92
- CNEY $0.14
- Average True Range (ATR)
- REVB 0.27
- CNEY 0.01
- MACD
- REVB 0.03
- CNEY 0.00
- Stochastic Oscillator
- REVB 28.44
- CNEY 21.32
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.